Exact Sciences
Interim Data From Mainz Biomed Study Boosts Profile of Next-Generation Colorectal Cancer Test
Premium
The interim results found the ColoAlert test had a sensitivity of 94 percent and specificity of 97 percent, with sensitivity for advanced adenoma of 80 percent.
Exact Sciences Sues Geneoscopy, Alleging Patent Infringement
Exact Sciences claims that Geneoscopy's ColoSense colorectal cancer screening assay infringes upon a patent covering Exact's Cologuard assay.
The company's data, presented at a recent meeting and simultaneously published, showed performance results analogous to currently marketed tests.
The company recently shared positive results from its Blue-C study, intended to support an FDA approval bid for a second generation of its colon cancer screening test.
Top Five Articles on 360Dx Last Week: Fight Brewing Over New FDA LDT Proposal; Medicare Fraud; More
Last week, readers were most interested in a story about another battle brewing over FDA's newest plans for regulating LDTs.
Aug 2, 2023
Jun 1, 2023
360Dx Top 30 Drops 6 Percent in May
Feb 1, 2023